Article

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

06/11/2025

Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the…

Read More

EQUAL Study Launches Lung Cancer Screening Trial for People at High Risk

06/10/2025

Dana-Farber Cancer Institute investigators launch a first-of-its-kind study to use a novel blood test to identify people who have never used tobacco but are at a high risk of lung cancer and offer them complimentary lung cancer screening. Excerpt from the Press Release: Dana-Farber Cancer Institute researchers have launched a study of a novel, homegrown…

Read More

Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

06/09/2025

Excerpt from the Press Release: FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead…

Read More

RevBio Expands Globally into the United Kingdom with its Second Cranial Flap Fixation Clinical Trial for its Regenerative Bone Adhesive

06/05/2025

This Clinical Trial will Demonstrate the Use of TETRANITE® to Reintegrate Cranial Bone Flaps for Improved Clinical Outcomes Excerpt from the Press Release: LOWELL, Mass.–(BUSINESS WIRE)–RevBio, Inc., announced that it has received approval from the Medicines and Health Regulatory Agency (MHRA) to conduct a 15 patient pilot clinical trial to use TETRANITE® to reintegrate bone…

Read More

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

06/04/2025

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ Excerpt from the Press Release: LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) — uniQure…

Read More

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

06/03/2025

New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS…

Read More

Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies

06/03/2025

Novel approach targeting KAT2A/B with preclinical validation across multiple cancer models and tumor types Excerpt from the Press Release: NEWTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the first patient has been dosed with…

Read More

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

06/02/2025

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program Excerpt from the Press Release: WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or…

Read More

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

05/30/2025

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for…

Read More

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

05/29/2025

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor Excerpt from the Press Release: SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology…

Read More